mRNA Patent Wars Update: Litigations Expand and Key Rulings Expected in 2025

Join Rothwell Figg Partner Dan Shores as he gives a mRNA patent wars update.

While the COVID-19 pandemic caused tragedy for millions of families worldwide, it has also spurred concomitant advancements in health care, not the least of which include the first-ever regulatory approvals of therapies based on messenger RNA (mRNA) technology granted to Moderna and BioNTech (in collaboration with Pfizer).

At the dawn of this new era in therapeutics, companies operating in this space are eager to develop and commercialize new mRNA-based drugs, but are also faced with the significant challenge of navigating an exceedingly complex IP and competitive landscape involving mRNA and lipid nanoparticle delivery technologies. As a backdrop to these challenges is ongoing high-stakes litigation among major market players which largely began in 2022 based on the sales of the Moderna and BioNTech/Pfizer vaccines that obtained approval to combat the pandemic.

This webinar will provide a detailed update on those cases, including summaries of several key rulings occurring and anticipated this year, and provide analytical frameworks for companies to utilize when navigating this complex space.

 

 

 

Webinar Resources